Johnson & Johnson has made it to the list of top 10 most innovative companies in the world released by FOREX.com.
The US-based pharmaceutical company is the fourth most innovative company, scoring 8.23/10 in the innovation index.
Johnson & Johnson is the only pharmaceutical company making it to top 10 list, which makes it the world's most innovative pharmaceutical company in 2023.
The ranking is based on many factors such as the number of US-registered patents in 2022, the number of R&D expenses over the last 12 consecutive months and
their last reported intangible assets.
The health giant spent £37.16 billion on intangible assets (the second highest after Apple), £11.87 billion on R&D last year and registered 1,377 patents last year.
US pharmaceutical giant Johnson & Johnson on Friday (November 12) announced plans to break up into two listed companies, separating its consumer health arm that sells Band-Aids and Tylenol from its pharmaceutical division.
Johnson & Johnson said in a statement it will create "two global leaders that are better positioned to deliver improved health outcomes for patients and consumers through innovation."
It plans to complete the separation in 18-24 months, creating two publicly traded companies. CEO Alex Gorsky said the decision was made following a "comprehensive
review."
The board and management believe the split is "the best way to accelerate our efforts to serve patients, consumers, and healthcare professionals, create opportunities
for our talented global team, drive profitable growth, and -- most importantly -improve healthcare outcomes for people around the world," he said.
Johnson & Johnson said on Wednesday (January 18) that it was pulling the plug on a late-stage global trial of an HIV vaccine after the shot was found ineffective
at preventing infections.
The failure of the trial marks yet another setback in the search for a vaccine against a virus known to mutate rapidly and find unique ways to evade the immune
system, and comes more than a year after another of J&J's HIV vaccine failed a study.
"It's not the outcome we had hoped for, unfortunately," said a spokesperson for the National Institute of Allergy and Infectious Diseases, a J&J partner in the trial.
"The development of a safe and effective HIV vaccine has been a considerable scientific challenge, but we will learn from this study and continue forward."
The trial involved administering two different types of a shot, which uses a cold-causing virus to deliver the genetic code of HIV, spread over four vaccination
visits in a year. J&J used similar technology for its COVID-19 vaccine.
The study, which began in 2019, was conducted at over 50 sites and included about 3,900 gay men and transgender people - groups that are considered vulnerable to
the infection.
Doc Johnson Jenna's Perfect Pair UR3 By Doc Johnson - with price: $24,197.78 - Anatomically right shape of Jenna Jameson's bosoms made altogether of UR3-Doc Johnson Ultra Realistic 3.0 material, exploratorily advanced patented elastic compound that copies the feel of human substance. Feeling
Prime minister Boris Johnson received his Covid-19 booster shot on Thursday (December 2) and urged others to follow suit to help the country fend off the Omicron variant of coronavirus.
Wearing a mask, Johnson briefly chatted to staff and others queuing for their shots at the vaccination centre in central London, asking them if they were there to receive a booster dose and thanking them for attending.
Johnson, who said it could "have gone either way" when he was treated in hospital for Covid last year, was later filmed rolling up his shirt sleeve and receiving his shot.
"Fantastic. Thank you so much," he said to the nurse, before receiving a badge that said "I've boosted my immunity".
Health secretary Sajid Javid and chancellor of the exchequer Rishi Sunak have both resigned on Tuesday (July 5) after a slew of scandals undermined the
government of prime minister Boris Johnson.
Javid and Sunak sent resignation letters to Johnson within minutes of each other in which both took aim at his ability to run an administration that adhered to
standards.
The resignations came as Johnson was apologising for appointing a lawmaker to a role involved in offering pastoral care, even after being briefed that the politician
had been the subject of complaints about sexual misconduct.
In his resignation letter to Johnson, Javid said "it is clear to me that this situation will not change under your leadership - and you have therefore lost my
confidence too".
He was appointed to lead the Department of Health and Social Care in June 2021, when his predecessor Matt Hancock quit after being caught having an affair with an
adviser, in breach of social distancing guidelines.
Around 90 percent of coronavirus patients in intensive care units have not had a booster jab, prime minister Boris Johnson said on Wednesday (December 29) - defending his decision not to tighten virus curbs in England.
Speaking at a vaccination centre, Johnson urged people to get "vital" booster jabs, saying "the overwhelming majority" of those currently going into intensive care in our hospitals have not had the booster jab.
"I've talked to doctors who say the numbers are running up to 90 percent of people in intensive care who are not boosted," the prime minister added in Milton Keynes in Hertfordshire.
Those who have not been vaccinated are "eight times more likely to get into hospital," he warned.
The UK has been hit by a huge surge of the new Omicron variant, with England and Wales reporting record case numbers on Tuesday. The UK has been one of Europe's worst hit with a death toll of 148,021.
Prime minister Boris Johnson announced on Wednesday (January 19) that restrictions re-imposed in England last month would be lifted by from next Thursday (January 27).
In the latest development, the government has decided to end the guidance on working from home, asking employers to make adequate arrangements to return safely to work.
From the start of next Thursday, mandatory certification based on vaccines and tests will end, however, organisations can still choose to use the NHS Covid Pass voluntarily.
Besides, the legal mandate to wear face masks will go away from next week.
Making a statement to the House of Commons on Covid-19, he said that infection levels are falling in England mainly because of the country's "extraordinary booster campaign".
He noted more than 36 million Covid-19 booster jabs had been delivered, with over 90 percent of over-60s now given a third dose.
"Our scientists believe it is likely that the Omicron wave has now peaked nationally," Johnson added, while cautioning "the pandemic is not over".
"I encourage everyone across the country to continue with all the cautious behaviours that we know help to keep each everybody safe."
In what's seen as a major step forward for the treatment of schizophrenia, the Medicines and Healthcare Products Regulatory Agency (MHRA) has authorised a
new Johnson & Johnson drug in Britain.
Byannli is a six-monthly paliperidone palmitate (PP6M) and is the first long-acting injectable schizophrenia treatment which offers patients the potential for up to
six months of symptom control and a reduction in their risk of relapse with only two doses a year.
It is a long-acting injectable that works by dissolving and entering the bloodstream slowly, due to its extremely low water solubility, resulting in continuous
absorption of paliperidone palmitate over a six-month period.
"Schizophrenia is a chronic and severe brain disorder, and antipsychotic medication plays an important role in its treatment. However, many people with the illness
experience relapses which are often caused by poor adherence to oral medication," said Prof David Taylor, director of Pharmacy and Pathology at the Maudsley Hospital.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the Scottish Medicines Consortium (SMC) has approved Ponvory (ponesimod) for treating adults with relapsing-remitting multiple sclerosis (RRMS) within NHS Scotland.
Ponesimod offers an additional treatment choice for the ailment, which affects over 15,000 people in Scotland.
Multiple sclerosis (MS) is a chronic autoimmune inflammatory disease of the central nervous system in which immune cells attack myelin, causing inflammation.
The common symptoms of this disease include fatigue, balance and walking problems, numbness or tingling, dizziness and vertigo.
Amanda Cunnington, director of Health Economics, Market Access, Reimbursement, Government Affairs & Patient Engagement, Janssen-Cilag Limited said: "This decision
further supports our commitment to ensuring patients living with this condition have access to new treatment options to help address some of the life-long and life-limiting symptoms of MS.
Prime minister Borris Johnson visited a Boots vaccination site in his west London constituency of Uxbridge on Monday (January 10) - as the pharmacy chain celebrates its anniversary of supporting the NHS Covid-19 vaccination drive.
During the visit, the prime minister met with some pharmacists who have been administering Covid-19 booster jabs to patients.
Since opening the first vaccination site at its Halifax store in January 2021, Boots UK has administered over 1.4 million Covid-19 jabs, and continues to offer booster doses at over 80 pharmacies, the company said in a statement.
Continuing its support for the Covid-19 booster programme, Boots has doubled appointment capacity and added a small number of new sites since December 2021.
Boots vaccination programme director Nick Sunderland said: "We are so proud of our pharmacists who have worked incredibly hard to support the national effort to accelerate the Covid-19 booster vaccination programme.
Shares in GSK, Sanofi and Haleon fell sharply on Thursday (August 11) amid growing investor concerns about US litigation focused on a heartburn drug that
contained a probable carcinogen, while Johnson and Johnson has decided to end sales of talcum powder after cancer claims.
GSK shares were down 6.8 per cent, Sanofi's were down 6.9 per cent and Haleon's down per cent.
GSK and Sanofi at various points sold the drug - originally branded as Zantac - which US regulators ordered off the market in 2020. Haleon, spun out as an independent
listed company last month, comprises consumer health assets once partly owned by GSK.
The prospect of impending litigation is not new. Among other disclosures, recently-listed Haleon had highlighted the risk of such lawsuits in its prospectus.
The topic has arrived in investor consciousness in recent days it seems, but has been rumbling on in the background for a few years, Deutsche Bank analysts wrote in a
note.
Former pharmacy minister Steve Brine was on Wednesday (November 2) elected chair of the influential Health and Social Care Committee, the cross-party
parliamentary group that scrutinises the work of the Department of Health and Social Care and its associated public bodies.
The Conservative MP for Winchester won 253 out of 432 votes beating off four other contenders for the role - Stephen Hammond, Dr Caroline Johnson, Anne Marie Morris
and James Morris - in a four-stage election in which MPs voted by ranking candidates in order of preference. Dr Johnson, who was Mr Brine's main challenger, bagged
148 votes in the final round.
An election for a new chair of the Health and Social Care Committee was triggered following the resignation of Jeremy Hunt MP who was appointment as chancellor of
the exchequer on October 14.
Issuing a statement after his election, Mr Brine said: "I welcome the opportunity as chair to continue the calm, measured work of Jeremy Hunt and to examine new
solutions to support the NHS to enable it to continue providing the services that we all depend upon."
Charac, an NHS-integrated one-stop platform for independent community pharmacies, has secured £1 million strategic investment from the Royal Mail Group,
enabling its time-saving platform to assist more local pharmacies and patients across the UK to easily manage their prescriptions and consultations online.
The company said this new money will enable it to leverage strong levels of trust that pharmacists enjoy within the communities they serve in and will ensure
pharmacies remain a cornerstone of vibrant high streets and an invaluable provider of frontline healthcare products and services, including vitally needed
consultations.
Charac says it is aiming to sign up over 1,000 UK pharmacies in the next 12 months by expanding its geographic footprint beyond current cities, including London,
Manchester and Birmingham, and targeting small multiple and independent pharmacies, accounting for almost 40 per cent of the UK's community pharmacy network.
The announcement also sees the addition of Stefan Kulik, a managing director at Royal Mail, to the Charac board. Stefan is responsible for leading Royal Mail's
expansion into the healthcare industry and brings a breadth of experience, having previously worked in healthcare with companies including Johnson & Johnson.
Former chancellor Rishi Sunak, one of two candidates vying to be Britain's next premier, criticised the way outgoing prime minister Boris Johnson handled the
Covid-19 pandemic, saying it had been a mistake to "empower" scientists and that the downsides of lockdowns were suppressed.
The Tories are choosing a new leader after Johnson was forced to quit when dozens of ministers resigned in protest at a series of scandals and missteps. Party members
are voting to select either Sunak or foreign secretary Liz Truss, who will take over next month.
Opinion polls show Sunak is behind in race. The handling of the pandemic has become an issue, with Truss saying this month she would never again approve another
lockdown and also asserting that as trade minister at the time she was not involved in taking the key decisions about how to respond.
Sunak said the government had been "wrong to scare people" about coronavirus. He said he was banned by officials in Johnson's office from discussing the "trade-offs"
of imposing coronavirus-related restrictions, such as the impact on missed doctor's appointments and lengthening waiting lists for healthcare in the NHS.
Covid-19 vaccine makers are shifting gears and planning for a smaller, more competitive booster shot market after delivering as many doses as fast as they
could over the last 18 months.
Executives at the biggest Covid vaccine makers including Pfizer and Moderna said they believe most people who wanted to get vaccinated against Covid have already done so - more than five billion people worldwide.
In the coming year, most Covid vaccinations will be booster shots, or first inoculations for children, which are still gaining regulatory approvals around the world, they said.
Pfizer, which makes its shot with Germany's BioNTech and Moderna still see a major role for themselves in the vaccine market even as overall demand declines.
Upstart US vaccine maker Novavax and Germany's CureVac, which is working with GlaxoSmithKline, are developing vaccines they hope to target at the booster market.
The roles of AstraZeneca and Johnson & Johnson, whose shots have been less popular or effective, are expected to decline in this market.
Amgen Inc on Monday agreed to buy Horizon Therapeutics Plc in a deal valued at $27.8 billion (£22.67bn), fortifying its rare diseases portfolio in the biggest
buyout in the sector this year.
The company will pay $116.50 in cash, a premium of nearly 20 per cent to the stock's last close, for each Horizon share.
Horizon shares closed up 15 per cent on Monday at $112.36. They had climbed 23.5 per cent through Friday since the company disclosed in late November it was in
preliminary talks with Amgen, Sanofi and Johnson & Johnson for potential offers. Amgen shares dipped less than 1 per cent to close at $276.78.
Sanofi said Sunday it ended discussions with Horizon after concluding the transaction prices "do not meet our value criteria."
J&J also said in early December that it had dropped its pursuit of the deal.
A three-wheeled wheelchair was built in 1655 or 1680 by a disabled German man, Stephan Farffler, who wanted to be able to maintain his mobility. Since he was a watch-maker, he was able to create a vehicle that was powered by hand cranks.
In 1789, two French inventors developed a three wheeled vehicle, powered by pedals; They called it the tricycle.
19th century tricycle used in Iran
In 1818, British inventor Denis Johnson patented his approach to designing tricycles.[clarification needed] In 1876, James Starley developed the Coventry Lever Tricycle, which used two small wheels on the right side and a large drive wheel on the left side; power was supplied by hand levers. In 1877, Starley developed a new vehicle he called the Coventry Rotary, which was "one of the first rotary chain drive tricycles." Starley's inventions started a tricycling craze in Britain; by 1879, there were " twenty types of tricycles and multi-wheel cycles ... produced in Coventry, England, and by 1884, there were over 120 different models produced by 20 manufacturers." The first front steering tricycle was manufactured by The Leicester Safety Tricycle Company of Leicester, England in 1881 which was brought to the market in 1882 costing £18. They also developed a folding tricycle at the same time.Buy online Tricycle for handicapped and disabled at lowest price and cheap cost in india from wheelchair india online shopping store of Tricycle manufacturer, distributor, dealer and supplier of variety of Tricycles at low price in india for handicapped and disability product like Disabled Tricycle Deluxe Double Hand Drive, Tricycle Deluxe Single Hand Drive, Tricycle Standard Double Hand Drive, Tricycle Regular Single Hand Drive, Standard Single Hand Drive Tricycle, along with that we offer huge discount.
Tricycles were used by riders who did not feel comfortable on the high wheelers, such as women who wore long, flowing dresses. In the UK, upright tricycles are sometimes referred to as "ba